$226 Million is the total value of ARMISTICE CAPITAL, LLC's 27 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RTRX | Exit | RETROPHIN INC | $0 | – | -34,874 | -100.0% | -0.20% | – |
| UNXLQ | Exit | UNI PIXEL INC | $0 | – | -176,000 | -100.0% | -0.48% | – |
| DRRX | Exit | DURECT CORP | $0 | – | -3,849,266 | -100.0% | -1.46% | – |
| Exit | CENVEO CORPnote 7.000% 5/1 | $0 | – | -3,752 | -100.0% | -1.79% | – | |
| Exit | EXELIXIS INCnote 4.250% 8/1 | $0 | – | -6,678 | -100.0% | -1.82% | – | |
| BSTC | Exit | BIOSPECIFICS TECHNOLOGIES CO | $0 | – | -105,000 | -100.0% | -1.95% | – |
| KND | Exit | KINDRED HEALTHCARE INC | $0 | – | -234,000 | -100.0% | -2.04% | – |
| UNTD | Exit | UNITED ONLINE INC | $0 | – | -350,000 | -100.0% | -2.45% | – |
| URBN | Exit | URBAN OUTFITTERS INC | $0 | – | -172,000 | -100.0% | -2.90% | – |
| LF | Exit | LEAPFROG ENTERPRISES INCcl a | $0 | – | -1,500,000 | -100.0% | -3.40% | – |
| TIME | Exit | TIME INC NEW | $0 | – | -310,000 | -100.0% | -3.67% | – |
| AEGR | Exit | AEGERION PHARMACEUTICALS INC | $0 | – | -372,000 | -100.0% | -3.74% | – |
| SODA | Exit | SODASTREAM INTERNATIONAL LTD | $0 | – | -430,000 | -100.0% | -4.16% | – |
| HPTX | Exit | HYPERION THERAPEUTICS INC | $0 | – | -434,000 | -100.0% | -5.00% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -9,400,000 | -100.0% | -6.19% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC | 30 | Q3 2023 | 2.7% |
| SPDR S&P 500 ETF TR | 28 | Q3 2023 | 29.5% |
| MADRIGAL PHARMACEUTICALS INC | 27 | Q3 2023 | 2.9% |
| VANDA PHARMACEUTICALS INC | 26 | Q3 2021 | 9.4% |
| REGENERON PHARMACEUTICALS | 25 | Q3 2023 | 3.2% |
| ENERGIZER HLDGS INC NEW | 22 | Q2 2023 | 3.7% |
| ANTARES PHARMA INC | 21 | Q3 2020 | 6.6% |
| INCYTE CORP | 21 | Q3 2023 | 2.8% |
| VOYAGER THERAPEUTICS INC | 21 | Q3 2023 | 2.0% |
| BLUEBIRD BIO INC | 20 | Q4 2021 | 1.8% |
View ARMISTICE CAPITAL, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Avalo Therapeutics, Inc. | June 28, 2023 | 588,850 | 4.7% |
| Addex Therapeutics Ltd. | February 16, 2023 | 675,295 | 5.0% |
| Arcadia Biosciences, Inc. | February 14, 2023 | 2,675,409 | 10.0% |
| Avinger Inc | February 14, 2023 | 789,400 | 10.0% |
| Baudax Bio, Inc. | February 14, 2023 | 1,165,709 | 5.0% |
| BIORA THERAPEUTICS, INC. | February 14, 2023 | 12,989,648 | 5.7% |
| Bit Digital, Inc | February 14, 2023 | 3,161,889 | 3.7% |
| Bruush Oral Care Inc. | February 14, 2023 | 1,122,922 | 10.0% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Clarus Therapeutics Holdings, Inc. | February 14, 2023 | 2,732,169 | 5.0% |
View ARMISTICE CAPITAL, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View ARMISTICE CAPITAL, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.